| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 8
| Issue : 1 | Page : 87-91 |
|
|
Interim analysis report of kuanxiong aerosol in improving angina and quality of life after percutaneous coronary intervention
Luo-Qi Lin1, Bing-Xin Wu1, Miao-Yang Lin1, Qiu-Xiong Chen2, Dan-Ping Xu3
1 The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China
2 Department of Cardiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
3 Department of Cardiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Postdoctoral Research Station, Institute of Integrative Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China
Correspondence Address:
Prof, Dan-Ping Xu
Department of Cardiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120; Postdoctoral Research Station, Institute of Integrative Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122
China
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/wjtcm.wjtcm_26_21
|
|
|
Objective: The objective is to observe the effect of Kuanxiong aerosol (KXA) on angina and the quality of life of patients after percutaneous coronary intervention (PCI). Materials and Methods: Six hundred patients with angina after PCI (AAP) were randomly assigned to an experimental group and a control group (n = 300 in each group) and received basic treatment with KXA or basic treatment (respectively) for 8 weeks. The Seattle Angina Questionnaire (SAQ) and visual analog scale (VAS) scores of the two groups during the screening period and five follow-up periods were compared. Results: A total of 179 patients were included in this interim report, including 85 in the experimental group and 94 in the control group. Among the five-dimensional scores of the SAQ, the improvement in the angina frequency and quality of life scores in the experimental group was better than those in the control group after treatment (P < 0.01), and the difference in scores of the remaining dimensions was not statistically significant (P > 0.01). The difference in VAS scores between the two groups was not statistically significant (P > 0.01). No obvious adverse reactions were observed between the two groups. Conclusions: KXA can reduce the frequency of AAP and improve patients' quality of life.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
